8NE:FRA
Lisata Therapeutics, Inc.
0,82 €
arrow_downward
-0,61%(-0,0050) 1D
13-окт., 11:46:17 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 8NE...
Open
0,82 €
High
0,82 €
Low
0,82 €
Mkt. cap
10,80 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
4,34 €
52-wk low
0,74 €
No. of employees
21
Open
0,82 €
High
0,82 €
Low
0,82 €
Mkt. cap
10,80 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
4,34 €
52-wk low
0,74 €
No. of employees
21
News stories
From web sources and news partners
The Seattle Times
·
15 мүнөт мурун
The first big batch of US profit reports for the summer has Wall Street mixed
Yahoo Finance
·
30 мүнөт мурун
A Look Back at Digital Media & Content Platforms Stocks’ Q2 Earnings: People (NASDAQ:PPLI) Vs The Rest Of The Pack
Bloomberg.com
·
3 саат мурун
S&P 500 Record Rally Meets Risk of Peaking Earnings Growth
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersБаскинг Ридж, Нью Джерси, Америка Кошмо Штаттары
Sector-
Websitelisata.com